Colchicine: Difference between revisions
| Line 10: | Line 10: | ||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
*Familial Mediterranea Fever (FMF) | |||
==Special Populations== | ==Special Populations== | ||
Revision as of 12:55, 16 June 2016
Administration
- Type: Antigout
- Dosage Forms: capsules, tablets
- Routes of Administration: Oral
- Common Trade Names: Colcris; Mitigare (US), Jamp-Colchicine, PMS-Colchicine
Adult Dosing
- Flare treatment: Initial: 1.2 mg and then 0.6 mg in an hour (maximum 1.8 mg within 1 hour). In patient receiving prophylaxis treatment wait for 12 h after flare dosing before resuming prophylaxis dose. Do not repeat treatment for at least 3 days (Canadian labelling recommendation)
- Prophylaxis Treatment: 0.6 mg twice daily (maximum 1.2 mg/day) for 3 months (without tophi) to 6 months (≥1 tophi) after reaching target serum uric acid levels [1]
Pediatric Dosing
- Familial Mediterranea Fever (FMF)
Special Populations
Renal Dosing
- Adult:
- Pediatric:
Hepatic Dosing
- Adult:
- Pediatric:
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
Common
Pharmacology
- Half-life:
- Metabolism:
- Excretion:
Mechanism of Action
Comments
See Also
References
- ↑ Khanna D. et al.2012 ACR Guidelines for Management of Gout Part I: Systemic Non-pharmacologic and Pharmacologic Therapeutic Approach to Hyperuricemia. Arthritis Care Res (Hoboken). 2012 Oct; 64(10): 1431–1446.